Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Operating Expenses: 2011-2025

Historic Other Operating Expenses for Fennec Pharmaceuticals (FENC) over the last 3 years, with Sep 2025 value amounting to $5.9 million.

  • Fennec Pharmaceuticals' Other Operating Expenses fell 1.48% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.1 million, marking a year-over-year decrease of 11.26%. This contributed to the annual value of $21.6 million for FY2024, which is 61.49% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Other Operating Expenses is $5.9 million, which was up 10.32% from $5.3 million recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Other Operating Expenses peaked at $6.0 million during Q3 2024, and registered a low of -$10.0 million during Q2 2022.
  • In the last 3 years, Fennec Pharmaceuticals' Other Operating Expenses had a median value of $4.6 million in 2024 and averaged $4.5 million.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Other Operating Expenses spiked by 124.84% in 2023, and later plummeted by 42.35% in 2025.
  • Quarterly analysis of 4 years shows Fennec Pharmaceuticals' Other Operating Expenses stood at -$10.0 million in 2022, then soared by 124.84% to $4.6 million in 2023, then increased by 1.32% to $4.6 million in 2024, then dropped by 1.48% to $5.9 million in 2025.
  • Its Other Operating Expenses stands at $5.9 million for Q3 2025, versus $5.3 million for Q2 2025 and $3.3 million for Q1 2025.